Home » Stocks » Qualigen Therapeutics

Qualigen Therapeutics, Inc. (QLGN)

Stock Price: $5.62 USD 0.21 (3.88%)
Updated Aug 12, 2020 2:37 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 94.58M
Revenue (ttm) 5.56M
Net Income (ttm) -7.09M
Shares Out 16.83M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $5.62
Previous Close $5.41
Change ($) 0.21
Change (%) 3.88%
Day's Open 5.41
Day's Range 4.91 - 5.75
Day's Volume 2,976,860
52-Week Range 3.71 - 30.75

More Stats

Market Cap 94.58M
Enterprise Value 88.70M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 16.83M
Float 4.69M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -6.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 248,166
Short Ratio 0.11
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17.02
PB Ratio 18.86
Revenue 5.56M
Operating Income -8.28M
Net Income -7.09M
Free Cash Flow -9.14M
Net Cash 5.88M
Net Cash / Share 0.35
Gross Margin 6.74%
Operating Margin -149.02%
Profit Margin n/a
FCF Margin -164.40%
ROA -24.46%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$175.00*
Low
175
Current: $5.62
High
175
Target: 175.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-10.84-17.89-7.90-18.45-8.91-2.28
Net Income-10.13-16.87-7.86-18.38-8.79-2.47
Shares Outstanding0.380.210.090.040.01-
Earnings Per Share-26.50-91.50-123.75-510.00-777.50-1,697.50
Operating Cash Flow-14.52-13.33-7.40-15.21-5.72-1.16
Capital Expenditures---0.01-0.01-0.02-
Free Cash Flow-14.52-13.33-7.41-15.22-5.74-1.16
Cash & Equivalents1.7014.8022.637.0515.822.75
Total Debt0.10-----
Net Cash / Debt1.6014.8022.637.0515.822.75
Assets2.8015.3222.837.2416.042.96
Liabilities1.705.932.713.131.3517.46
Book Value1.109.3920.134.1014.68-14.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Qualigen Therapeutics, Inc.
Country United States
CEO Michael S. Poirier

Stock Information

Ticker Symbol QLGN
Stock Exchange NASDAQ
Unique Identifier NASDAQ: QLGN

Description

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.